CurrentEndo
Get Weekly

CurrentEndo coverage · page 41 of 55

Diabetes, Obesity and Metabolism

Briefs 1,601–1,640 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    A predictive model for medium‐term weight loss response in people with type 2 diabetes engaging in behavioural weight management interventions

    Diagnostic or prognostic studyObesity

  2. Diabetes Obes Metab

    Association between new‐onset atrial fibrillation and dementia among individuals with type 2 diabetes

    Cohort studyT2D & other

  3. Diabetes Obes Metab

    Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study

    Cohort studyT2D & other

  4. Diabetes Obes Metab

    Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add‐on therapy in drug‐naïve patients with type 2 diabetes ( TRIPLE ‐ AXEL study): A multicentre, randomized, 104‐week, open‐label, active‐controlled trial

    Randomized controlled trialT2D & other

  5. Diabetes Obes Metab

    Cost–utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy—An Italian healthcare system perspective

    Research articleTechnology

  6. Diabetes Obes Metab

    Association between longitudinal changes in body composition and the risk of kidney outcomes in participants with overweight/obesity and type 2 diabetes mellitus

    Secondary analysisComplications

  7. Diabetes Obes Metab

    Biological aging mediates the associations of metabolic score for insulin resistance with all‐cause and cardiovascular disease mortality among US adults: A nationwide cohort study

    Cohort study

  8. Diabetes Obes Metab

    Moderate resistance training reduces intermuscular adipose tissue and risk factors of atherosclerotic cardiovascular disease for elderly patients with type 2 diabetes

    Randomized controlled trialT2D & other

  9. Diabetes Obes Metab

    Cumulative effect of metabolic risk factors on left ventricular geometry in those with versus without early‐onset type 2 diabetes or prediabetes: The Coronary Artery Risk Development in Young Adults (CARDIA) study

    Cohort studyT2D & other

  10. Diabetes Obes Metab

    Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin

    Research articleT2D & other

  11. Diabetes Obes Metab

    Exploring causal effects of gut microbiota and metabolites on body fat percentage using two‐sample Mendelian randomization

    Diagnostic or prognostic studyObesity

  12. Diabetes Obes Metab

    Differential associations of risk factors with severe and non‐severe hypoglycaemia: the Hypoglycaemia Assessment Tool prospective observational study in people with insulin‐treated type 1 diabetes and type 2 diabetes

    Cohort studyComplications

  13. Diabetes Obes Metab

    Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme

    Cohort studyT2D & other

  14. Diabetes Obes Metab

    A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects

    Randomized controlled trialT2D & other

  15. Diabetes Obes Metab

    Plasma fatty acid esters of hydroxy fatty acids and surrogate fatty acid esters of hydroxy fatty acids hydrolysis activity in children with or without obesity and in adults with or without coronary artery disease

    Cross-sectional studyObesity

  16. Diabetes Obes Metab

    Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial

    Diagnostic or prognostic studyT2D & other

  17. Diabetes Obes Metab

    Association of dipeptidyl peptidase‐4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability

    Cohort studyT2D & other

  18. Diabetes Obes Metab

    Long‐term changes in frailty and incident type 2 diabetes: A prospective cohort study based on the UK Biobank

    Cohort studyT2D & other

  19. Diabetes Obes Metab

    Association between two novel anthropometric measures and type 2 diabetes in a Chinese population

    Cohort studyT2D & other

  20. Diabetes Obes Metab

    Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population

    Cohort studyT2D & other

  21. Diabetes Obes Metab

    Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes

    Cohort studyT2D & other

  22. Diabetes Obes Metab

    The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis

    Cohort studyLipids & liver

  23. Diabetes Obes Metab

    Association between recent exposure to continuous glucose monitoring‐recorded hypoglycaemia and counterregulatory and symptom responses to subsequent controlled hypoglycaemia in people with type 1 diabetes

    Mechanistic studyTechnology

  24. Diabetes Obes Metab

    Cross‐sectional association of continuous glucose monitoring‐derived metrics with cerebral small vessel disease in older adults with type 2 diabetes

    Cross-sectional studyComplications

  25. Diabetes Obes Metab

    Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease

    Secondary analysisT2D & other

  26. Diabetes Obes Metab

    Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials

    Meta-analysisLipids & liver

  27. Diabetes Obes Metab

    Total and H‐specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration

    Randomized controlled trialObesity

  28. Diabetes Obes Metab

    Development and first‐stage validation of a digital version of the Digit Symbol Substitution test for use in assessing cognitive function in older people with diabetes

    Diagnostic or prognostic studyT2D & other

  29. Diabetes Obes Metab

    Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies

    Randomized controlled trialT2D & other

  30. Diabetes Obes Metab

    Effects of gut microbiome on type 1 diabetes susceptibility and complications: A large‐scale bidirectional Mendelian randomization and external validation study

    Diagnostic or prognostic studyT1D

  31. Diabetes Obes Metab

    A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes

    Cohort study

  32. Diabetes Obes Metab

    Determinants of serious health outcome‐free status in middle‐aged and older people with dysglycaemia: Exploratory analysis of the ORIGIN trial

    Secondary analysisT2D & other

  33. Diabetes Obes Metab

    Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists

    Cohort studyT2D & other

  34. Diabetes Obes Metab

    Modelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease: A pilot study

    Research articleObesity

  35. Diabetes Obes Metab

    Metformin use associated with lower rate of hospitalization for influenza in individuals with diabetes

    Cohort studyT2D & other

  36. Diabetes Obes Metab

    Cardiometabolic factors and population risks of cardiovascular disease in community‐dwelling adults with varied blood pressure statuses

    Cohort study

  37. Diabetes Obes Metab

    Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide

    Research articleT2D & other

  38. Diabetes Obes Metab

    Validation of the Individualized Metabolic Surgery score in predicting long‐term remission of diabetes after duodenal switch‐type procedures

    Cohort studyObesity

  39. Diabetes Obes Metab

    Factors affecting the sodium‐glucose cotransporter 2 inhibitors‐related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database

    Cohort studyComplications

  40. Diabetes Obes Metab

    Frequency of prediabetes in individuals with increased adiposity and metabolically healthy or unhealthy phenotypes

    Cross-sectional studyT2D & other

All 2,200 Briefs in ExploreShowing Briefs 1,601–1,640 of 2,200, newest first